We are live on ! Find out more
AVDL

Avadel Pharmaceuticals
AVDL

Delisted

AVDL was delisted on the 11th of February, 2026.

Back to rankings

175 hedge funds and large institutions have $613M invested in Avadel Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 60 increasing their positions, 45 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 26

33% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 45

10% more funds holding

Funds holding: 159 → 175 (+16)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

1.93% less ownership

Funds ownership: 82.51% → 80.58% (-1.9%)

27% less capital invested

Capital invested by funds: $836M → $613M (-$223M)

44% less call options, than puts

Call options by funds: $2.25M | Put options by funds: $3.99M

Holders
175
Holders Change
+16
Holders Change %
+10.06%
% of All Funds
2.34%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
43
Increased
60
Reduced
45
Closed
26
Calls
$2.25M
Puts
$3.99M
Net Calls
-$1.74M
Net Calls Change
-$15.2M

Top Buyers

Rank Fund Capital Flow
1
BIP
Brandes Investment Partners
California
+$29.3M
2
Bank of America
Bank of America
North Carolina
+$8.67M
3
KAM
Krensavage Asset Management
New York
+$7.96M
4
TSC
Two Seas Capital
New York
+$5.44M
5
TCM
Tang Capital Management
California
+$5.02M

Top Sellers

Rank Fund Capital Flow
1
B
Braidwell
Connecticut
-$43.2M
2
TLP
Tri Locum Partners
New York
-$20.4M
3
Goldman Sachs
Goldman Sachs
New York
-$11.9M
4
CC
Checkpoint Capital
California
-$10.6M
5
Millennium Management
Millennium Management
New York
-$9.35M
Name Holding Trade Value Shares
Change 		Change in
Stake
Nuveen
26
Nuveen
North Carolina
$4.06M +$1.78M +212,477 +70%
Deutsche Bank
27
Deutsche Bank
Germany
$3.95M -$32.7K -3,906 -0.8%
D.E. Shaw & Co
28
D.E. Shaw & Co
New York
$3.87M +$1.55M +185,020 +60%
DMKJ
29
David M. Knott Jr
$3.34M +$662K +79,096 +23%
ACM
30
Altium Capital Management
New York
$3.28M -$279K -33,344 -7%
Ameriprise
31
Ameriprise
Minnesota
$2.94M +$304K +36,321 +11%
Renaissance Technologies
32
Renaissance Technologies
New York
$2.67M -$392K -46,800 -12%
Barclays
33
Barclays
United Kingdom
$2.62M +$1.38M +164,505 +97%
Marshall Wace
34
Marshall Wace
United Kingdom
$2.46M +$2.63M +314,343 New
Susquehanna International Group
35
Susquehanna International Group
Pennsylvania
$2.19M +$16.9K +2,019 +0.7%
Squarepoint
36
Squarepoint
New York
$2.08M +$1.16M +138,496 +109%
CM
37
Caption Management
Oklahoma
$2.07M +$2.22M +264,910 New
IAM
38
Iridian Asset Management
Connecticut
$1.95M +$670K +80,000 +47%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$1.83M +$75.6K +9,025 +4%
ICM
40
Invenomic Capital Management
Massachusetts
$1.79M +$1.91M +228,026 New
Charles Schwab
41
Charles Schwab
California
$1.77M +$30.5K +3,641 +2%
State of Wisconsin Investment Board
42
State of Wisconsin Investment Board
Wisconsin
$1.76M +$932K +111,302 +98%
AAS
43
Avantax Advisory Services
Texas
$1.74M +$471K +56,277 +34%
Fidelity Investments
44
Fidelity Investments
Massachusetts
$1.73M +$675K +80,585 +57%
NPT
45
National Philanthropic Trust
Pennsylvania
$1.72M – – –
JGC
46
J. Goldman & Co
New York
$1.69M +$1.47M +175,653 +435%
MML Investors Services
47
MML Investors Services
Massachusetts
$1.52M +$226K +27,000 +16%
DFCM
48
Dark Forest Capital Management
Puerto Rico
$1.4M +$1.5M +179,437 New
Swiss National Bank
49
Swiss National Bank
Switzerland
$1.32M -$20.1K -2,400 -1%
CSS
50
Cubist Systematic Strategies
Connecticut
$1.18M +$1.26M +150,451 New
1
2
3 4 5

AVDL Hedge Fund Activity: Q1 2025 in Review

175 of the 7,464 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q1 2025, worth a combined $613M — down 27% from $836M a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new AVDL positions and 26 closed out — a net gain of 17 holders — while 60 added to existing stakes and 45 trimmed.

The largest buyer was Brandes Investment Partners, adding an estimated $29.3M. The largest seller was Braidwell, exiting entirely with an estimated $43.2M sold.

  • 175 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q1 2025, up from 159 in Q4 2024.
  • Funds reported $613M of Avadel Pharmaceuticals stock for Q1 2025, down 27% quarter-over-quarter.
  • 43 funds opened new Avadel Pharmaceuticals positions in Q1 2025 and 26 closed out, a net change of +17 holders.
  • The largest Avadel Pharmaceuticals buyer in Q1 2025 was Brandes Investment Partners, an estimated $29.3M added.
  • The largest Avadel Pharmaceuticals seller in Q1 2025 was Braidwell, an estimated $43.2M sold.

Based on aggregated 13F filings for Q1 2025.